InDex Pharmaceuticals Holding AB (publ) published its interim report Q1 for January-March 2022 on May 16, 2021 at 08:00 a.m. CEST.

  • 01 Jun
    Annual General Meeting 2022
  • 02 Jun
    Presentation at Redeye Growth Day
  • 09 Jun
    Deep dive presentation: commercialisation strategy for cobitolimod at HC Andersen Capital’s online event

Our phase III study CONCLUDE

Have a look at InDex’s corporate presentation

InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis

Proud partner of: